[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase I results of its oral GLP-1 receptor agonist CT-996 for the treatment of people with obesity

Roche announced positive topline results from a Phase I clinical trial for CT-996, an oral GLP-1 receptor agonist for type 2 diabetes and obesity. The study showed that CT-996 led to clinically meaningful weight loss of 6.1% in participants with obesity without diabetes after four weeks. CT-996 was well-tolerated, with mostly mild to moderate gastrointestinal side effects and no drug-related discontinuations. Blood levels of CT-996 remained stable regardless of meal timing, suggesting flexible dosing options. The drug's mechanism of action targets cAMP signaling with minimal beta-arrestin recruitment, potentially leading to better glycemic control and weight loss. Roche's Chief Medical Officer expressed enthusiasm for the results, highlighting CT-996's potential for chronic weight management and glycemic control. The study results will be presented at an upcoming medical meeting, and CT-996 will advance to Phase II clinical development. Obesity is a pressing global health concern with various comorbidities, and current treatments are often inadequate. CT-996 is part of Roche's expanding metabolic portfolio, aiming to provide diverse treatment options for obesity, diabetes, and other cardiometabolic diseases. Roche is committed to scientific excellence and personalized healthcare, collaborating with partners to improve global healthcare access.